Open Position

 

Lab Facilities

 

Complete CV 

 

Collaborators

Research Areas

Recent News/Events

 UT College of Pharmacy Website: http://pharmacy.utmem.edu

Mahato’s Lab website Address:  http://www.utmem.edu/Mahato_Lab

Center for Cancer Research at UT Website:       http://www.utmem.edu/cancer/

Ram I. Mahato, Ph.D.

Professor (Tenured)
Department of Pharmaceutical Sciences
University of Tennessee Health Science Center
Cancer Research Building

19 South Manassas (Room 224)

Memphis, TN 38103-3308
Tel: (901) 448-6929 (office), 448-6848 (Lab)
Fax: (901) 448-2099
E-mail: rmahato@utmem.edu
http://cop.utmem.edu/rmahato

 

 

EDUCATION AND PROFESSIONAL EXPERIENCE:

Education: Ph.D. in Pharmaceutics and Drug Delivery from the University of Strathclyde, Britain (1989-92), B.S. in Pharmaceutics from China Pharmaceutical University, China. (1985-89), Diploma in Chinese from Beijing Language Institute, China (1984-85), Certificate Level in Science from Tribhuwan University, Nepal (1981-83).

 

Professional Experience:

Professor (2009-present), Associate Professor(2005-2009), Assistant Professor (2001-2005), Department of Pharmaceutical Sciences, University of Tennessee Health Science Center, Research Assistant Professor, Department of Pharmaceutics and Pharmaceutical Chemistry, University of Utah (1999-2001), Senior Scientist, Gene Delivery Sciences, GeneMedicine, inc. (Valentis, Inc., 1996-99), Research Scholar, Gene Delivery Sciences, Faculty of Pharmaceutical Sciences, Kyoto University, Japan (1994-96), Postdoctoral Fellow, Departments of Chemical Engineering and Ophthalmology, Washington University, St. Louis (1993-1994), Research Associate, Department of Pharmaceutical Sciences, University of Southern California, Los Angeles (1992).  

 

HONORS AND AWARDS:

2009       Permanent Member of the BTSS study section of the NIH from July 2009-June 2013

2009       Outstanding Teaching Awards, College of Graduate Health Sciences, Univ. of Tennessee

2009       Invited to Diabetes and Obesity Global Therapeutic Expert Forum, Merck & Co., May 2-3, 2009,

               New York

2006       Nonviral Gene Transfer Vectors Scientific Committee Member, American Society of Gene Therapy; Symposium Chair, Biomaterials for Site-specific Delivery of Oligonucleotides and siRNA, National Biotechnology Conferences (June 18-21, Boston, MA)

2005       Short Course Chair, Pharmaceutical Perspectives of Synthetic and Hybrid Vectors-based Nucleic Acid Therapeutics, 2005 AAPS Annual Meeting and Exposition (Nashville, 2005)

2004       Invited Speaker, Modulation of Gene Expression by Antisense, Antigene and sRNAi, 31st Controlled Release Society (CRS) Annual Meeting (Hawai, 2004); Invited Speaker, Viral Medicine? Never, Pearls of Wisdom, 31st Controlled Release Society (CRS) Annual Meeting (Hawai, 2004);

2003:      Invited Speaker, Challenges of Antisense Oligonucleotide Delivery, 30th Controlled Release Society (CRS) Annual Meeting (Glasgow, UK, 2003); Who’sWho in America (2003)

2002:      Invited Speaker on Functional and Biospecific Polymers for Therapeutic Gene Delivery, AAPS Workshop on Critical Issues in the Design & Applications of Polymeric Biomaterials in Drug Delivery (Arlington, VA, 2002)

               Session Chair, Therapeutic Gene/Oligonucleotide Delivery, 29th CRS Annual Meeting (Seoul, Korea, 2002)

2000       Invited Speaker on Introduction to Gene Therapy at Sunrise School of Pharmacy at the AAPS Annual Meeting (Indianapolis, 2000)

1999       Invited Speaker, Tailor made polymeric gene carriers at the 3rd Congress of Eur Assoc Clin Pharmacol Ther (EACPT) (Jerusalem, Israel, 1999)

1995-96 Goho Foundation Fellowship (Japan) 

1994-95 Uehara Foundations Fellowship (Japan)

1989-92 Cancer Research Campaign PhD Studentship of the United Kingdom

1986       International Student Award by China Pharmaceutical University, China

1984-8    Undergraduate studies supported by the Ministry of Education, Nepal

 

NATIONAL AND INTERNATIONAL SCIENTIFIC REVIEW PANELS:

  1.  PCRP Clinical & Experimental Therapeutics #1 Panel Meeting, Department of Defense, July 26-28, 2009.

  2. 2009/10 ZRG1 SBIB-V (58) RFA OD-09-003 NIH Challenge Panel#23 and BST-M (58) RFA OD-09-003 Challenge Grants Panel 4

  3. National Institutes of Health, Bioengineering, Technology and Surgical Sciences (BTSS) Study Section, May 18-19, 2009.

  4. World Class University (WCU) International Review Panel, WCU-KOSEF, Washington, DC., April 5-6, 2009.

  5. 2009 Prostate Cancer Research Program - PRE-CET-B, April 2009.

  6. National Institutes of Health, Bioengineering, Technology and Surgical Sciences (BTSS) Study Section, February 8-9, 2009.

  7. Susan G. Komen for the Cure: Localized Chemotherapies, 2009.

  8. National Institutes of Health, Bioengineering, Technology and Surgical Sciences (BTSS) Study Section, October 6-7, 2008.

  9. Clinical & Experimental Therapeutics-3 (CET-3) Panel Meeting, Department of Defense, July 20-22, 2008.

  10. National Institutes of Health, Bioengineering, Technology and Surgical Sciences (BTSS) Study Section, May 19-20, 2008.

  11. National Institutes of Health, Bioengineering, Technology and Surgical Sciences (BTSS) Study Section, February 4-5, 2008.

  12. Susan G. Komen for the Cure Panel Meeting at Alexandria, VA, January 10-11, 2008.

  13. National Institutes of Health, Special Emphasis Panel on Enzyme Assessment Core, NIDDK, November 15, 2007.

  14. Clinical & Experimental Therapeutics-3 (CET-3) Panel Meeting, Department of Defense, August 15-17, 2007.

  15. Israel Science Foundation, March 2007.

  16. Wellcome Trust, Great Britain, January 2007.

  17. Alberta Heritage Foundation for Medical Research, Canada, December 2006.

  18. National Institutes of Health, Nanoscience and Nanotechnology, Washington D.C., July 2004.

  19. National Institutes of Health, Nanoscience and Nanotechnology (Washington D.C., March 2004

  20. James and Esther King Biomedical Research Program, 2004-Present.

  21. Engineering & Biological Systems (EBS) of Great Britain, April, 2004.

  22. American Institute of Biological Sciences, October-November, 2002.

  23. National Institutes of Health, Gene Therapy Panel, March, 2002.

SERVICE TO PROFESSIONAL ASSOCIATIONS:

Moderator

1.   Site-specific Delivery and Targeting of Nucleic Acids for treating Fibrosis, 2008 National Biotechnology Conference (NBC), Toronto, Canada, June, 2008.

2.     Nanoencapsulation I, 34th Controlled Release Society Annual Meeting, Long Beach, CA, July, 2007.

3.    Session 13: Solutions to Novel Drug Delivery System, 5th Annual Drug Discovery Conference and Expo (IDDST), Shanghai, China, May 27-31, 2007.

4.    Biomaterials for Site-specific Delivery of Oligonucleotides and siRNA; and Emerging Trends in Cell-Based Therapeutics, National Biotechnology Conferences, Boston, MA, June 18-21, 2006.

5.    Delivery, Transport and Transcription, 9th Annual Meeting of American Society of Gene Therapy (ASGT), Baltimore, MD, May 31-June 4, 2006.

6.    Short Course Chair on Pharmaceutical Perspectives of Synthetic and Hybrid Vectors-based Nucleic Acid Therapeutics, AAPS Annual Meeting and Exposition, Nashville, October, 2005.

7.    Delivery of Nucleotide-based Therapeutics, 32nd Controlled Release Society Annual Meeting (Miami, Florida, 2005)

8.  Workshop Chair on Pharmaceutical Perspectives of Nucleic Acid-Based Therapeutics, 31st Controlled Release Society (CRS) Annual Meeting, Hawaii, July, 2004.

9.  Challenges for Oligonucleotide Delivery, 30th Controlled Release Society Annual Meeting (Glasgow, Scotland, 2003)

10.  Therapeutic Gene/Oligonucleotide Delivery, 29th CRS Annual Meeting, Seoul, Korea, July, 2002.

 Symposia/Workshop Organizer

  1. Workshop on siRNA Delivery at SMi Group’s 6th Conference on Controlled Release, London, UK, March 11-12, 2009 (Role: Organizer)

  2. CRS 2008 Educational Workshop Review Committee, 35th Controlled Release Society Annual Meeting, New York, NY (Role: Member)

  3. Workshop Chair on Pharmaceutical Perspectives of Nucleic Acid-Based Therapeutics, 31st Controlled Release Society (CRS) Annual Meeting, Hawaii, July, 2004 (Role: Organizer)

  4. Round-table on Disposition of Nonviral Gene Delivery Systems and Oligonucleotides. Annual AAPS Meeting, San Francisco, CA, November, 1998 (Role: Co-organizer along with Shankar Musunuri and Uday B. Kompella). 

  5. Member, 2007 CRS/Jorge Heller Journal of Controlled Release Award Committee.

 

EDITORIAL ACTIVITIES:

  Editor:                Pharmaceutical Research

 Editorial Board: Journal of Drug Targeting

Expert Opinion on Drug Delivery

Transplantation & Risk Management

Inflammation & Allergy-Drug Targets

 

RESEARCH SUPPORT:

ACTIVE:

NIH 2R01        DK69968-05

Principal Investigator:                Ram I. Mahato, Ph.D.

Growth Factor Gene Delivery to Human Pancreatic Islets

The goal of this project is to develop adenovirus-based growth factor and antiapoptotic gene delivery to human pancreatic islets for treatment of type I diabetes.  

 

NIH 1 R01 EB003922-02                                 03/01/07– 02/28/10                           

Principal Investigator:                               Ram I. Mahato, Ph.D.

Targeted Delivery of TFOs for Treatment of Liver Fibrosis

The major goal of this project is to targeted delivery of a1(I) collagen gene promoter specific triplex forming oligonucleotides (TFOs) to liver fibrogenic cells in fibrotic rats after conjugation with mannose 6-phosphate-bovine serum albumin (M6P-BSA) via a disulfide bond.

NIH/R01  DK64366-01A1        01/01/04-12/31/08

Principal Investigator:   Ramareddy V. Guntaka, Ph.D.

Coinvestigator:              Ram I. Mahato, Ph.D.

A Promoter-Specific TFO Prevents Liver Fibrosis

Fibrosis is due to abnormal accumulation of type I collagen in the interstitial space of various organs. The goal of this project is to use a triplex-forming oligonucleotide as an antigene agent targeting the promoter of a1(I) collagen gene.

 

UT Rheumatic Diseases Research Core Center Grant   9/01/04-9/30/06

Principal Investigator:   Ram I. Mahato, Ph.D.

Targeted Delivery of Oligonucleotides into Hepatic Stellate Cells

The goal of this project is to develop receptor-mediated delivery strategies for oligonucleotides to hepatic stellate cells to inhibit collagen production for treatment of liver fibrosis. 

 

Teaching and Faculty Responsibilities:

·         PHSC111: Physical Pharmacy to PharmD Students

·         PHSC911: Delivery and Biocompatibility of Protein and Nucleic Drugs to Graduate Students

·        Director, Graduate Seminar Programs and courses (PHAC 819, PHAC 919, MEDC 819, and MEDC 919), UTHSC

·        Member, Graduate Curriculum  and Faculty Development Committees, University of Tennessee Health Science Center,  Memphis, TN

 

RESEARCH ACTIVITIES/INTERESTS:

These are exciting times in the scientific world.  The public all over the world is fascinated by the spectacular advances in gene therapy, sequencing of the human genome, and stem cell research.  These advances promise to prevent, correct or modulate genetic and acquired diseases, which use genes to produce therapeutic proteins or inhibit aberrant protein production.  The launching of the human proteome project has turned functional genomics and proteomics into powerful bullworks, which will give us an integrated scenario of turning nucleic acids into therapeutics.  The development of effective nucleic acid therapeutics demands teamwork among scientists with expertise in molecular and cell biology, biochemistry, biophysics, polymer chemistry, colloid science, pharmaceutics, and medicine. In the last decade, significant progress has been made in the use of nucleic acids, such as plasmid DNA, antisense oligonucleotides, siRNA, ribozymes, peptide nucleic acids (PNA) and aptamer nucleic acids for nucleic acid therapy. 

Our research involves in the following distinct arena: (i) Delivery of Oligonucleotides, siRNA and shRNA for Treatment of Hepatitis, Liver Fibrosis, Diabetes; Prostate Cancer and Hepatocellular Carcinoma (ii) Design and Synthesis of Novel Polymers, Lipopeptides, Lipopolymers and Cationic Lipids for Nucleic Acid Delivery, (iii) Design and Construction of Novel Plasmid and Adenovirus-based Gene and shRNA Expression Systems, (iv) Formulation and In Vitro Characterization of Nucleic Acid Delivery Systems to various Disease Targets, (v) Mechanisms of Cellular Uptake and Intracellular Trafficking of Nucleic Acid Drugs, (vi) Therapeutic Gene Delivery to Pancreatic Human Islets for the Treatment of Diabetes, (vii) Targeted Delivery of Triplex-Forming Oligonucleotides (TFO) and siRNA for the Treatment of Hepatitis and Fibrosis, and (viii) Micellar Drug Delivery for treating Prostate Cancer. We attempt to understand the genesis of structure-synthesis-function interrelationships. How the components of a viable gene expression system would influence the disease state by controlling gene regulation, transcription, translation and replication are also the central theme of our research. 

 

BOOK EDITOR:

  1.  Narang AS and Mahato RI (Eds) Targeted Delivery of Small and Macromolecular Drugs, CRC Press, Inc., FL (in review process )

  2. Lu Y and Mahato RI (eds) Pharmaceutical Perspectives of Cancer Therapeutics, Springer/AAPS Publication (in press)

  3. Mahato RI. Pharmaceutical Dosage Forms and Drug Delivery(2007), CRC Press, Inc., FL

  4. Mahato RI (Ed) Biomaterials for Delivery and Targeting of Proteins and Nucleic Acids (2005), CRC Press, Inc., FL

  5.  Mahato RI and Kim SW (Eds) Pharmaceutical Perspectives of Nucleic Acid-Based Therapeutics (July 2002), Francis and Taylor, London.

 

JOURNAL THEME ISSUE EDITOR:

  1. Cheng K and Mahato RI (Eds) Special Issue on siRNA Delivery (2009) Mol. Pharm. 6: 649-50.

  2. Lee M and Mahato RI (Eds) Special Issue on the Gene Regulation for Effective Gene Therapy (2009) Adv. Drug Del. Rev. 61: 487-488.

  3. Ye Z and Mahato RI (Eds) Special Issue on the Emerging Trends in Cell-based Therapeutics (2008) Adv Drug Del Rev 60: 89-90

  4. Mahato RI (Ed) Special Issues on Gene Delivery and Targeting (1999 and 2000) Journal of Drug Targeting 7: 241-313; 7: 407-470; and 8: 1-66. 

  5. Mahato RI (Ed) Theme Issue on Challenges of Turning Nucleic Acids into Therapeutics (2000) Adv. Drug Del. Rev. 44 (2-3): 79-207. 

 

 EDITORIALS & COMMENTARIES/BOOK REVIEWS:

  1. Cheng K and Mahato RI (2009) siRNA Delivery and Targeting. Mol Pharm 6: 649-50. 

  2. Lee M and Mahato RI (2009) Gene Regulation for Effective Gene Therapy. Adv. Drug Del. Rev. 61: 487-488.

  3. Ye Z and Mahato RI (2008) Role of nanomedicines in cell-based therapeutics. Nanomedicines 3: 5-8.  

  4. Mahato RI and Narang AS (2005) Need of closer alliances for turning nucleic acids into nanomedicines. CRS Newsletter 22(1): 22, 25, 31.

  5. Book Review: A. Rolland and S.M. Sullivan, Editors, Pharmaceutical Gene Delivery Systems, Marcel Dekker, New York (2004) (424 pp.), J Control Rel 104: 233-234.

  6. Mahato RI (2000) Challenges of turning nucleic acids into therapeutics. Adv Drug Deliv Rev 44: 79-80.

  7. Mahato RI (1999): Editorial: Plasmid-based gene therapy: Opportunities and challenges knock the millennium. J Drug Target 7: 241-244.

  8. Mahato RI, Fons MP and A Rolland (1998) Nonviral gene therapy: From Bench to the Clinic. CRS Newsletter 15: 9-11.

 

 PATENTS & INVENTION DISCLOSURES: 

  1. RI Mahato, AO Gaber, AS Narang, D Fraga and M Kotb (2003) Vascular endothelial growth factor gene delivery to human islets for neoangiogenesis after transplantation.  Filed for patent by the University of Tennessee Health Science Center, Memphis

  2. RI Mahato, A Maheshwari and SW Kim (2005) Soluble steroidal peptides for nucleic acid delivery. US Patent# 6,875,611 and  7,320,890 B2

  3. RI Mahato, SO Han and DY Furgeson (2004) Cationic lipopolymer as biocompatible gene delivery agent. US Patent# 6,696,038.

 

RESEARCH PAPERS:

  1. Li F and Mahato RI (2009) Bipartite Vectors for co-expression of a Growth Factor cDNA and shRNA against an Apoptotic Gene. J Gene Med (in press)

  2. Cheng K, Yang N and Mahato RI (2009) TGF-β1 Gene Silencing for Treating Liver Fibrosis. Mol Pharm 6: 772-9.

  3. Danquah M, Li F, Duke III C, Miller DD and Mahato RI (2009) Micellar Delivery of Bicalutamide and Embelin for Treating Prostate Cancer. Pharm Res (published online)

  4. Yang N, Ye Z, Li F and Mahato RI (2009) HPMA Polymer-based Site-specific Delivery of Oligonucleotides to Hepatic Stellate Cells. Bioconjugate Chem 20: 213-221.

  5. Panakanti R and Mahato RI (2009) Bipartite Adenoviral Vector encoding hVEGF and hIL-1Ra for Improved Human Islet Transplantation.  Mol Pharm 6: 274-284.

  6. Zhu L, Lu Y, Miller DD and Mahato RI (2008) Structural and Formulation Factors Influencing Pyridinium Lipid-based Gene Transfer. Bioconjugate Chem 19: 2499-2512.

  7. Panakanti R and Mahato RI (2009) Bipartite Adenoviral Vector encoding hHGF and hIL-1Ra for Improved Human Islet Transplantation.  Pharm Res 26: 587-596.

  8. Cheng G, Zhu L and Mahato RI (2008) Caspase-3 Gene Silencing for inhibiting Apoptosis in Insulinoma Cells and Human Islets. Mol Pharm 5: 1093-1102.

  9. Li F and Mahato RI (2008) iNOS gene silencing prevents inflammtory cytokine induced beta cell apoptosis. Mol Pharm 5: 407-417.

  10. Chen Y and Mahato RI (2008) siRNA Pool targeting different sites of human hepatitis B surface antigen efficiently inhibits HBV infection. J Drug Target 16:140-148.

  11. Zhu L, Ye Z, Cheng K, Miller DD and Mahato RI (2008) Site-specific delivery of oligonucleotides to hepatocytes after systemic administration. Bioconjugate Chem 19:290-8.

  12. Ye Z, Guntaka RV and Mahato RI (2007) Sequence-specific triple helix formation with genomic DNA. Biochemistry 46: 11240-11252.

  13. De Paula D, Bentley MV and Mahato RI (2007) Effect of iNOS and NF-kB gene silencing on β-cell survival and function. J Drug Target 15: 358-369.

  14. Jia X, Cheng K and Mahato RI (2007) Co-expression of vascular endothelial growth factor and interleukin-1 receptor antagonist for improved human islet survival and function. Molecular Pharmaceutics 4: 199-207.

  15. Narang AS, Sabek O, Gaber AO, and Mahato RI (2006) Co-expression of vascular endothelial growth factor and interleukin-1 receptor antagonist improves human islet survival and function. Pharm Res 23: 1970-1982.

  16. Ye Z, Cheng K, Guntaka RV and Mahato RI (2006) Receptor-mediated Hepatic Uptake of M6P-BSA-conjugated Triplex Forming Oligonucleotides in Rats. Bioconjugate Chem 17: 823-830.

  17. Cheng K, Ye Z, Guntaka RV and Mahato RI (2006) Enhanced hepatic uptake and bioactivity of type a1(I) collagen gene promoter specific triplex forming oligonucleotides after conjugation with cholesterol. J Pharmacol Exp Ther 317: 797-805.

  18. Cheng K, Ye Z, Guntaka RV and Mahato RI (2005) Biodistribution and Hepatic Uptake of Triplex Forming Oligonucleotides Against Type ?1(I) Collagen Gene Promoter in Normal and Fibrotic Rats. Molecular Pharmaceutics 2: 206-217.

  19. Ye Z, Cheng K, Guntaka RV and Mahato RI (2005) Targeted delivery of triplex forming oligonucleotides to hepatic stellate cells. Biochemistry 44: 4466-4476.

  20. Narang AS, Thoma L, Miller DD, Mahato RI (2005) Cationic lipids with increased DNA binding affinity for nonviral gene transfer in dividing and nondividing cells. Bioconjug Chem 16: 156-168.

  21. Cheng K, Fraga D, Kotb M, Gaber AO, Guntaka RV and Mahato RI  (2004) Adenovirus-based vascular endothelial growth factor gene delivery to human islets. Gene Ther11: 1105-1116.     

  22. Narang AS, Cheng K, Henry J, Zhang C, Sabek O, Fraga D, Kotb M, Gaber AO and Mahato RI (2004)  Vascular endothelial growth factor gene delivery to human islets for neoangiogenesis after transplantation.  Pharm Res. 21: 15-25.

  23. Mahato RI, Henry J, Narang AS, Sabek O, Fraga D, Kotb and Gaber AO (2003) Cationic lipid and polymer-based gene delivery to human pancreatic islets.  Mol. Ther. 7: 89-100.

  24. Wang D-A, Narang AS, Kotb M, Gaber OA, Miller DD, Kim SW and Mahato RI (2002) Novel branched poly(ethylenimine)-cholesterol water soluble lipopolymers for gene delivery. Biomacromolecules 3: 1197-1207.

  25. Maheshwari A, Mahato RI and Kim SW (2002) Biodegradable polymer-based interleukin-12 gene delivery: Role of induced cytokines, tumor infiltrating cells and nitric oxide in anti-tumor activity.  Gene Ther 9: 1075-1084.

  26. Furgeson DY, Cohen RN, Mahato RI and Kim SW (2002) Design, synthesis and characterization of novel lipoparticulates for systemic gene delivery.  Pharm Res 19: 382-390.

  27. Benns JM, Mahato RI and Kim SW (2002) Optimization factors influencing the transfection efficiency of folate-PEG-folate-graft-polyethylimine.   J Control Release 79: 255-269. 

  28. Benns JM, Maheshwari A, Furgeson DY, Mahato RI and Kim SW (2001) Folate-PEG-Folate-graft-polyethylenimine-based gene delivery.  J Drug Target. 9: 123-139. 

  29. Mahato RI, Lee M, Han S-O, Maheshwari A and Kim SW (2001) Intratumoral delivery of p2CMVmIL-12 using water soluble lipopolymers.  Mol Ther 4: 130-138.  

  30. Han S-O, Mahato RI and Kim SW (2001) Synthesis and characterization of water-soluble lipopolymer for gene delivery.  Bioconjug Chem 12: 337-345. 

  31. Maheshwari A, Mahato RI, McGregor J, Han S-O, Samlowski WE, Park J-S and Kim SW (2000) Soluble biodegradable polymer-based cytokine gene delivery for cancer treatment.  Mol Ther 2: 121-130. 

  32. Benns JM, Choi J-S, Mahato RI, Park J-S and Kim SW (2000) pH sensitive cationic polymer gene delivery vehicle: N-Ac-poly(L-histidine)-graft-poly(L-lysine) comb shaped polymer.  Bioconjug Chem 11: 637-645.

  33. Nomura T, Yamada T, Mahato RI, Watanabe Y, Takakura Y and Hashida M (1999) Gene expression and antitumor effects following direct interferon-g gene transfer with naked plasmid DNA and DC-Chol liposome complexes in mice.  Gene Ther 6: 121-129. 

  34. Mahato RI, Anwer K, Tagliaferri F, Meaney C, Leonard P, Chen W, French M, Wadhwa MS and Rolland A (1998) Biodistribution and gene expression of plasmid/lipid complexes after systemic administration in mice.  Hum Gene Ther 9: 2083-2099. 

  35. Takagi T, Hashiguchi M, Mahato RI, Tokuda H, Takakura Y and Hashida M (1998) Involvement of specific mechanism in plasmid DNA uptake by mouse peritoneal macrophages.  Biochem. Biophys. Res. Commun. 245: 729-733.  

  36. Mahato RI, Takemura S, Takakura Y and Hashida M (1997) Physicochemical and disposition characteristics of antisense oligonucleotides complexed with glycosylated poly(L-lysine). Biochem Pharmacol 53: 887-895. 

  37. Takakura Y, Mahato RI, Yoshida M, Kanamaru T and Hashida M (1996) Uptake characteristics of oligonucleotides in the isolated rat liver perfusion system. Antisense Res Develop 6: 177-183. 

  38. Sawai K, Mahato RI, Oka Y, Takakura Y and Hashida M (1996) Disposition of oligonucleotides in the isolated perfused rat kidney: Involvement of scavenger receptors in their renal uptake. J Pharmaco. Exp Ther 279: 284-290. 

  39. Hashida M, Mahato RI, Kawabata K, Sawai K, Nishikawa M and Takakura Y (1996) Pharmacokinetics of proteins, oligonucleotides, and genes.  J Contr Rel 41: 91-97. 

  40. Yoshida M, Mahato RI, Kawabata K, Takakura Y and Hashida M (1996) Disposition characteristics of plasmid DNA in the single-pass rat liver perfusion systems. Pharm Res 13: 597-601.

  41. Mahato RI, Kawabata K, Nomura T, Takakura Y and Hashida M (1995) Physicochemical and pharmacokinetic characteristics of DNA/cationic liposomes complexes. J Pharm Sci 84: 1267-1271. 

  42. Mahato RI, Kawabata K, Takakura Y and Hashida M (1995) In vivo disposition of plasmid DNA complexed with cationic liposomes. J Drug Target 3: 149.

  43. Mahato RI, Halbert GW, Willmott N and Vezin WR (1994) Micron-sized biodegradable microspheres: Characterization and preparative techniques. J Nep Pharm Assoc 18: 1-16. 

BOOK CHAPTERS

  1. Cheng G, Danquah M and Mahato RI (2008) MicroRNAs as therapeutic targets for cancer. In: Lu Y and Mahato RI (eds) Pharmaceutical Perspectives of Cancer Therapeutics. Springer, New York, NY (in press).

  2. Cheng K and Mahato RI (2006) Biopharmaceutical Challenges: Pulmonary Delivery of Proteins and Peptides. In: Meibohm B (ed) Pharmacokinetics and Pharmacodynamics of Biotech Drugs, Wiley-VCH Verlag GmbH & Co, Weinheim, p. 209-242.

  3. Mahato RI, Ye Z and Kim WS (2006) Water soluble lipopolymers and lipopeptides for nucleic acid delivery. In: Friedmann T and Rossi J (eds) Gene Transfer: Delivery and expression of DNA and RNA, A Laboratory Manual, Cold Spring Harbor Laboratory Press, New York, p. 501-506.

  4. Mahato RI and Kim SW (2005) Water soluble lipopolymers for gene delivery. In Amiji MM (ed) Polymeric Drug Delivery:Principles and Applications, CRC Press, Boca Raton, FL, p 175-186.

  5. Mahato RI, Ye Z and Guntaka RV (2005) Antisense and Antigene Oligonucleotides: Structure, Stability and Delivery. In Mahato RI (ed) Biomaterials for Delivery and Targeting of Protein and Nucleic acid Drugs, CRC Press, Boca Raton, FL

  6. Mahato RI (2003) Pharmaceutical delivery systems and dosage forms. In Gourley D and Eoff J (eds) APhA’s Complete Review for Pharmacy, Castle Connolly Publishers, New York (2004)

  7. Mahato RI and Tomlison E (2001) Plasmid-based gene therapy.  In: AM Hillery, AW Lloyd and J Swarbrick (eds) Drug Delivery and Targeting: For Pharmacists and Pharmaceutical Scientists, Taylor & Francis, London, pp. 372-397. 

  8. Mahato RI,  Furgeson DY, Maheshwari A,  Han SO and  Kim SW (2000) Polymeric gene delivery for cancer treatment.  In: K.D. Park, I.C. Kwon, N. Yui, S.Y. Jeong and K. Park (eds) Biomaterials and Drug Deliver towards New Millennium, Han Rim Won Publishing Co., Seoul, Korea, pp. 249-280.  

  9.  Takakura Y, Mahato RI, Nomura T, Sawai K, Yoshida M, Kanamaru T and Hashida M (1995) Development of delivery systems for antisense oligonucleotides. In: Ogata N, Kim SW, Feijen J and Okano T (eds) Advanced Biomaterials in Biomedical Engineering and Drug Delivery Systems, Springer,  New York, p. 357-358.

 

 REVIEW ARTICLES

  1. Kim HA, Mahato RI and Lee M (2009) Hypoxia-specific gene expression for ischemic disease gene therapy. Adv Drug Del Rev 61: 614-622.

  2. Mahato RI (2009) Expression and Silencing for Improved Islet Transplantation. J Control Release (in press)

  3. Chen Y, Cheng GF and Mahato RI (2008) RNAi for Treating Hepatitis B Viral Infection. Pharm Res 25: 72-86.

  4. Ye Z, Houssein HSH and Mahato RI (2007) Bioconjugation of Oligonucleotides for Treating Liver Fibrosis. Oligonucleotides 17: 349-404.

  5. Cheng K and Mahato RI (2007) Gene modulation for treating liver fibrosis. Crit Rev Ther Drug Carrier Syst 24:93-146.  

  6. De Paula D, Bentley MV and Mahato RI (2007) Hydrophobization and bioconjugation for enhanced siRNA delivery and targeting. RNA 13: 431-456.

  7. Narang AS and Mahato RI (2006) Biological and biomaterial approaches for improved islet transplantation. Pharmacol Rev 58: 194-243. 

  8. Mahato RI (2005) Water insoluble and soluble lipids for gene delivery. Adv Drug Del Rev 57: 699-712.

  9. Mahato RI, Cheng K and Guntaka RV (2005) Modulation of gene expression by antisense and antigene oligodeoxynucleotides and small interfering RNA. Expert Opinion on Drug Delivery 2: 3-28.

  10. Mahato RI, Narang AS, Thoma L and Miller DD (2003) Emerging rends in oral delivery of peptide and protein drugs. Crit Rev Ther Drug Carrier Syst 20: 153-214. 

  11. Han S-O, Mahato RI, Sung YK and  Kim SW (2000) Development of Biomaterials for Gene Therapy.  Mol Ther 2: 302-317.  

  12. Mahato RI  (1999) Non-viral peptide-based approaches to gene delivery J. Drug Target. 7: 249-268. 

  13. Mahato RI, Monera OD, Smith LC and Rolland A (1999) Peptide-based gene delivery. Cur Opin Mol Ther 2: 226-243.  

  14. Mahato RI, Smith LC and Rolland A (1999) Pharmaceutical perspectives of nonviral gene therapy.  Adv Genet 41: 95-156. 

  15. Takakura Y, Mahato RI and  Hashida M (1998) Extravasation of macromolecules.  Adv Drug Del Rev 34: 93-108. 

  16. Mahato RI,  Rolland A and  Tomlinson E (1997) Cationic lipid-based gene delivery systems: Pharmaceutical perspectives.  Pharm Res 14: 853-859. 

  17. Mahato RI, Takakura Y and  Hashida M (1997) Nonviral vectors for in vivo gene delivery: Physiochemical and pharmacokinetic considerations. Crit Rev Ther Drug Carrier Syst 14: 133-172. 

  18. Mahato RI, Takakura Y and  Hashida M (1997) Development of targeted delivery systems for nucleic acid drugs. J Drug Target 4: 337-357.

  19. Takakura Y, Mahato RI, Nishikawa M and Hashida M (1996) Control of pharmacokinetics of drugs using macromolecular carriers. Adv Drug Del Rev 19: 377-399.

INVITED SPEAKER (National/International Meetings)

  1. Non-viral-based Gene Delivery: Obstacles, Challenges and O, Annual American Physical Society Meeting, Pittsburgh, PA, March 16-20, 2009.

  2. Gene Delivery and Silencing for Improved Human Islet Transplantation, SMi Group’s 6th Conference on Controlled Release, London, UK, March 11-12, 2009.

  3. Viral and Nonviral Gene Delivery, Department of Pharmacy Practice and Biopharmaceutical Sciences, University of Illinois at Chicago, January 21, 2008.

  4. Gene Expression and Silencing for Improved Islet Transplantation, 14th International Symposium on Recent Advances in Drug Delivery Systems, in Salt Lake City, UT, February, 2009. 

  5. Site Specific Delivery and Targeting of Oligonucleotides and siRNA for Treating Liver Diseases, 2nd International Symposium for Intelligent Drug Delivery System, Seoul, Koreas, May 8-9, 2008.

  6. Targeted Delivery of Oligonucleotides and siRNA for Treating Liver Diseases, Singapore National University, May 6, 2008.

  7. Multiple Gene Silencing for Improved Islet Transplantation, Department of Materials Sciences, Seoul National University, Korea, May 7, 2008.

  8. Silencing of Multiple Antiapoptotic Genes for Improved Islet Transplantation, Nanyang University, Singapore, May 6, 2008.

  9. Gene Delivery and Silencing for treating Liver Diseases. School of Pharmacy, Chinese University of Hong Kong, May 5, 2008.

  10. Site Specific Delivery and Targeting of Oligonucleotides and siRNA for Treating Liver Diseases, School of Pharmacy, University of Minnesota, Minneapolis, March 27, 2008.

  11. Gene Expression and Silencing for Improved Human Islet Transplantation, School of Pharmacy, University of Kentucky, Lexington, KY, February 15, 2008.

  12. Gene Silencing for Improved Transplantation. Endocrinology Grand Round, University of Tennessee Health Science Center, Memphis, Jan 24, 2008.

  13. Site Specific Delivery and Targeting of Oligonucleotides and siRNA for Treating Liver Fibrosis and Hepatitis, School of Pharmacy, University of Manchester, United Kingdom, October 18, 2007.

  14. Site Specific Delivery and Targeting of Oligonucleotides and siRNA for Treating Liver Diseases, Department of Pharmacy, Ludwig-Maximilians-Universität, Munich, Germany, October 16, 2007.

  15. Delivery and Targeting of Oligonucleotides and siRNA, Pfizer Global Research & Development, St Louis, MO, September 27, 2007.

  16. Site-specific Delivery of Oligonucleotides and siRNA, Department of Macromolecular Science, Fudan University, Shanghai, China, May 31, 2007.

  17. Site-specific Delivery and Targeting of Nucleic Acid Drugs for Treating Liver Diseases, China Pharmaceutical University, Nanjing, China, May 30, 2007.

  18. Site-specific Delivery and Targeting of Oligonucleotides and siRNA for Treating Hepatitis and Liver Fibrosis, 5th Annual Drug Discovery Conference and Expo (IDDST), Shanghai, China, May 27-31, 2007.

  19. Site-specific Delivery of Nucleic Acids (ODNs and siRNA) for Treating Liver Fibrosis, University of London School of Pharmacy, April 26, 2007.

  20. ODN (antisense and antigene) and siRNA Delivery and Targeting, Industry and Health Authority Conference on: Oligonucleotide-based Therapeutics, Bethesda, MD, April 19-20, 2007.

  21. Site-specific Delivery of Oligonucleotides and siRNA for treating Liver Fibrosis, Endocrinology Grand Round, University of Tennessee Memphis, January 25, 2007.

  22. The Role of Scientific Journals on Our Travel to Gene and Nanoworld, Universidade de Sao Paulo, Brazil, August 29-31, 2006.

  23. Gene Therapy and Gene Silencing in Islet Transplant, Division of Endocrinology, University of Tennessee Memphis, August 22, 2006.

  24. Site-specific Delivery of Oligonucleotides and siRNA for Treatment of Liver Fibrosis, Faculty of Pharmaceutical Sciences, Utretch University, Netherlands, July 21, 2006

  25. Site-specific Delivery of TFO and siRNA for Treatment of Liver Fibrosis, School of Pharmacy, University of Southern California, Los Angeles, CA, March 31, 2006.

  26. Gene Expression and Silencing for Improved Islet Transplantation, School of Pharmacy, University of Wisconsin, WI, September 16, 2005.

  27. Targeted Delivery of Triplex Forming Oligonucleotides to Hepatic Stellate Cells for Treatment of Liver Fibrosis, School of Pharmacy, University of Toronto, Canada, June 2005.

  28. Site-specific Delivery of Triplex Forming Oligonucleotides for Treatment of Liver Fibrosis. School of Pharmacy, University of Arkansas, Little Rock, AR, April 2005.

  29. A Travel to Gene and Nanoworld: A seminar to PharmD students, School of Pharmacy, University of Arkansas, Little Rock, AR, April 2005.

  30. Modulation of Gene Expression by Antisense, Antigene and sRNAi’ 31th Annual Meeting of the Controlled Release Society, Hawai, July 2004.

  31. Viral Vector never!! Pearls of Wisdom,  31th Annual Meeting of the Controlled Release Society, Hawai, July 2004

  32. Viral and Non-viral Approaches to Human Islet Transplantation. Department of Allergy and Immunology, University of Tennessee, Memphis, December 8th, 2003

  33. Triplex forming Oligonucleotide Delivery, Enzon, Inc. in Piscataway, NJ. (October 2, 2003)

  34. Challenges for oligonucleotide delivery. 30th Annual Meeting of the Controlled Release Society, Glasgow, Great Britain, July 2003

  35. Vascular endothelial growth factor gene delivery to human islets for neoangiogenesis after transplantation, Department of Internal Medicinem Endocrinology and Diabetology, Universitat Sklinikum, Giessen, Germany, July 15, 2003

  36. Development of novel gene carriers and expression systems for the treatment of diabetes and cancer, Pharmaceutics and Biopharmacy at the Philipps-University, Marburg, Germany, July 16, 2003.

  37. Development of novel gene delivery systems for the treatment of diabetes and cancer, Department of Biopharmaceutics and Pharmaceutical Technology, University of Saarland, Saarbrucken, Germany, July 18, 2003.

  38. From bench to business: Tips for academics considering industrial careers, UT Graduate Research Student Day, May 2, 2003

  39. Functional Polymer and Lipid-based gene delivery for treatment of cancer and diabetes, School of Biomedical Engineering, University of Tennessee Memphis, October 4, 2002.

  40. Development of gene delivery and expression systems for treatment of cancer and diabetes, Vascular Biology Center of Excellence, University of Tennessee Memphis, October, 2002.

  41. Gene delivery and expression systems for treatment of cancer and diabetes, Hepatitis C Group, University of Tennessee Memphis, September, 2002.

  42. Lipopolymeric Gene Delivery for the treatment of diabetes, Department of Materials Science, University of Tokyo, Japan, July 15, 2002.

  43. Nonviral Approaches for Gene Delivery to Human Islets, Division of Stem Cell Regulation Research, Osaka University, School of Medicine, Japan. July 17, 2002.

  44. Development of Synthetic Gene Carriers, Department of Chemistry, College of Natural Sciences, Seoul National University, South Korea. July 24, 2002.

  45. Polymeric Gene Delivery for the Treatment of Cancer and Diabeties, University of Nebraska at Omaha, March 11, 2002.

  46. Functional and Biospecific Polymers for Therapeutic Gene Delivery at AAPS Workshop on Critical Issues in the Design & Applications of Polymeric Biomaterials in Drug  Delivery, Arlington , VA. (February 28 ~ March 1, 2002).

  47. Nonviral Gene Delivery, St. Jude’s Children’s Hospital, Memphis, November, 2001.

  48. Introduction to Gene Therapy at Sunrise School of Pharmacy Session at the AAPS Annual Meeting (Indianapolis), 2000.

  49.  Tailor made polymeric gene carriers at the 3rd Congress of Eur Assoc Clin Pharmacol Ther (EACPT), Jerusalem, Israel (3-8, Oct' 99).

 

ABSTRACTS AND PRESENTATIONS (*speaker)

  1. Mahato RI, Panakanti R, Li F and Cheng G (2009) Gene Delivery and Silencing for Improved Islet Transplantation, 14th International Symposium on Recent Advances in Drug Delivery Systems, in Salt Lake City, UT, February 15-18, 2009.

  2. Panakanti R, Cheng G and Mahato RI, (2009) Construction of bicistronic adenoviral vector encoding genes hHGF and hIL-1Ra for islet transplantation. AAPS Annual Meeting (Atlanta, GA, 2008)

  3. Li F, Cheng G and Mahato RI (2008) MicroRNA-Based shRNA for iNOS Gene Silencing. AAPS Annual Meeting (Atlanta, GA, 2008)

  4. Zhu L, Lu Y1, Miller DD and Mahato RI (2008) Enhancing Gene Delivery Using Pyridinium Cationic Lipids. AAPS Annual Meeting (Atlanta, GA, 2008)

  5. Yang N, Ye Z and Mahato RI (2008) Delivery of TFO Using HPMA Polymer for Liver Fibrosis Treatment. 35th Proc. Int. Symp. Control Rel. Bioact. Mater, New York, NY (July 2008)

  6. Li F, Lu Y, Miller DD and Mahato RI (2008) Galactose-conjugated Polymeric Micelles for Targeted Drug Delivery. 35th Proc. Int. Symp. Control Rel. Bioact. Mater, New York, NY (July 2008)

  7. Panakanti R, Cheng G and Mahato RI (2008) Bicistronic Adenoviral vector encoding hVEGF and hIL-1Ra for improving islet Transplantation. 11th Annual Meeting of the American Society of Gene Therapy, Boston, MA (May 28-June 1, 2008)

  8. Cheng G and Mahato RI (2008) MicroRNA-based Small Interfering RNA Silencing for Inhibiting Apoptosis. 11th Annual Meeting of the American Society of Gene Therapy, Boston, MA (May 28-June 1, 2008)

  9. Zhu L, Lu Y, Miller DD and Mahato RI (2007) Synthesis and Characterization of Pyridinium-based Cationic Lipids for Gene and siRNA Delivery. AAPS Annual Meeting (San Diego, CA, 2007)

  10. Ye Z, Guntaka RV and Mahato RI (2007) Quantification of Sequence-specific Triple Helix Formation. AAPS Annual Meeting (San Diego, CA, 2007)

  11. Zhu L, Ye Z, Cheng K, Miller DD and Mahato RI (2007) Site-specific Delivery of Oligonucleotides to Hepatocytes. 34th Proc. Int. Symp. Control Rel. Bioact. Mater, Long Beach, CA (July 2007).

  12. Li F, Panakanti R and Mahato RI (2007) Gene Expression and Silencing for Successful Islet Transplantation. 10th Annual Meeting of the American Society of Gene Therapy, Seattle, WA (May-June 2007)

  13. Chen Y , Ye Z and Mahato RI (2007)  siRNA Pool Targeting Different Sites of Human Hepatitis B Surface Antigen Efficiently Inhibits HBV Infection, 10th Annual Meeting of the American Society of Gene Therapy, Seattle, WA (May-June 2007)

  14. Ye Z, Guntaka RV and Mahato RI (2007) Sequence-specific Triple Helix Formation with Genomic DNA, 10th Annual Meeting of the American Society of Gene Therapy, Seattle, WA (May-June 2007)

  15. Zhu L, Lu Y, Miller DD and Mahato RI (2007) Synthesis and Characterization of Pyridinium Cationic Lipids for Nucleic Acid Delivery. AAPS PharmForum (Memphis, TN, 2007)

  16. Zhu L, Lu Y, Miller DD and Mahato RI (2007) Synthesis and Characterization of Pyridinium Cationic Lipids for Nucleic Acid Delivery. AAPS PharmForum (Memphis, TN, 2007) 

  17. Cheng K and Mahato RI (2007) TGF-β1 Gene Silencing for Treating Liver Fibrosis. AAPS PharmForum (Memphis, TN, 2007)

  18. *Cheng K and Mahato RI (2007) TGF-β1 Gene Silencing for Treating Liver Fibrosis. AAPS PharmForum (Memphis, TN, 2007)

  19. *Mahato RI, Cheng K, Ye Z, Chen Yong and Zhu L (2007) Site-specific Delivery and Targeting of Oligonucleotides and siRNA for Treating Hepatitis and Liver Fibrosis, 5th Annual Drug Discovery Conference and Expo (Shanghai, China, May , 2007).

  20. *Mahato RI, De Paula D, Jia X, Cheng K and Narang AS (2007) Gene expression and silencing for improved islet transplantation. Pharmaceutical Science World Congress (Amsterdam, The Netherlands, April 2007). 

  21. Jia X, Cheng K and Mahato RI (2006) Construction of Bicistronic Plasmid Encoding Human Vascular Endothelial Growth Factor (hVEGF) and Interleukin-1 Receptor Antagonist (hIL-1Ra) for Improving Human Islet Transplantation. AAPS Annual Meeting (San Antonio, TX, 2006)

  22. Cheng K, Miller DD and Mahato RI (2006) Application of TGF-β1 Specific siRNA for the Treatment of Liver Fibrosis. AAPS Annual Meeting (San Antonio, TX, 2006)

  23. Cheng K, Guntaka RV and *Mahato RI (2006) Conjugation with Cholesterol Enhances Hepatic Uptake and Bioactivity of Triplex Forming Oligonucleotides. 33rd Proc. Int. Symp. Control Rel. Bioact. Mater (Vienna, Austria).

  24. Ye Z, Guntaka RV and Mahato RI (2006) M6P-BSA-TFO for Treating Liver Fibrosis, National Biotechnology Conference (Boston, June 2006)

  25. Ye Z, Cheng K, Guntaka RV and Mahato RI (2005) Hepatic uptake and subcellular distribution of a triplex forming oligonucleotide-bovine serum albumin conjugate in rats. AAPS Annual Meeting (Nashville, TN, 2005).

  26. Cheng K, Ye Z, Guntaka RV and Mahato RI (2005) Hepatic uptake and subcellular distribution of a triplex forming oligonucleotide in rats. AAPS Annual Meeting (Nashville, TN, 2005).

  27. Narang A, Sabek O, Gaber A and Mahato RI (2005) Effect of interleukin-1 receptor antagonist and vascular endothelial growth factor gene expression on human islet graft survival and function. AAPS Annual Meeting (Nashville, TN, 2005).

  28. Narang A, Thoma L, Miller DD, Rao RK and Mahato RI (2005) Permeation of lipid-insulin conjugate across rat jejunum and Caco2 cell monolayer. AAPS Annual Meeting (Nashville, TN, 2005).

  29. Narang A and Mahato RI (2005) Comparative efficacy of interleukin-1 receptor antagonist and small interfering RNA mediated silencing of inducible nitric oxide synthase in rat pancreatic islets. AAPS Annual Meeting (Nashville, TN, 2005).

  30. *Ye Z, Cheng K, Guntaka RV and Mahato RI (2005) Site-Specific Delivery of Triplex Forming Oligonucleotides to Hepatic Stellate Cells. 32nd Proc. Int. Symp. Control Rel. Bioact. Mater (Miami, FL, 2005).

  31. *Narang AS, Fraga D, Gaber AO and Mahato RI (2005) Adenoviral Delivery of Interleukin-1 Receptor Antagonist Gene to Human Pancreatic Islets. 32nd Proc. Int. Symp. Control Rel. Bioact. Mater (Miami, FL, 2005).

  32. Narang AS, Seth P, Rao RK, Miller DD and Mahato RI (2005) Transepithelial Permeation of Insulin and Insulin Derivatives. 32nd Proc. Int. Symp. Control Rel. Bioact. Mater (Miami, FL, 2005).

  33. Cheng K, Ye Z, Guntaka RV and Mahato RI (2005) Biodistribution of Triplex Forming Oligonucleotides Against Typea1(I) Collagen Gene Promoter in Normal and Fibrotic Rats. 32nd Proc. Int. Symp. Control Rel. Bioact. Mater (Miami, FL, 2005).

  34. Ye Z, Guntaka RV and Mahato RI (2004) Targeting Triplex Forming Oligonucleotide to Hepatic Stellate Cells 31st Proc. Int. Symp. Control Rel. Bioact. Mater (Hawai, 2004).

  35. Narang AS, Thoma L, Miller DD and Mahato RI (2004) Effect of Cationic Lipid Headgroups on Gene Transfer. 31st Proc. Int. Symp. Control Rel. Bioact. Mater (Hawai, 2004).

  36. *Mahato RI, Cheng K, Fraga D, Gaber AO and Guntaka RV (2004) Adenovirus-Based Vascular Endothelial Growth Factor Gene Delivery to Human Pancreatic Islets. 31st Proc. Int. Symp. Control Rel. Bioact. Mater (Hawai, 2004).

  37. *Mahato RI and Guntaka RV (2004) Modulation of Gene Expression by RNAi, Antisense and Antigene. 31st Proc. Int. Symp. Control Rel. Bioact. Mater (Hawai, 2004).

  38. Narang AS, Fraga D, Zhang C, Sabek O, Kotb M, A. Gaber AO and Mahato RI (2003) Ex vivo vascular endothelial growth factor gene delivery to human pancreatic islets. AAPS Annual Meeting, Salt Lake City, Utah (October 26-30, 2003)

  39. Cheng K, Fraga D, Guntaka RV, Kotb M, Gaber AO and Mahato RI (2003) Adenovirus-based vascular endothelial growth factor gene delivery to human pancreatic islets. AAPS Annual Meeting, Salt Lake City, Utah (October 26-30, 2003)

  40. *Mahato RI and Guntaka RV (2003) Challenges for Oligonucleotide Delivery. Proc. Int. Symp. Control Rel. Bioact. Mater. 20: (Glasgow, Great Britain).

  41. Narang AS , Cheng K, Henry J, Zhang C, Fraga D, Sabek O, Kotb M, Gaber AO and Mahato RI (2003) Lipid-based gene delivery to human pancreatic islets. Proc. Int. Symp. Control Rel. Bioact. Mater. 20: (Glasgow, Great Britain)

  42. Kumar N, Z Ye, Thoma L, Miller DD and Mahato RI (2003) Design of PEI-based lipopolymeric carriers for gene delivery. Proc. Int. Symp. Control Rel. Bioact. Mater. 20: (Glasgow, Great Britain)

  43. Ye Z, Kumar N, Thoma L, Miller DD and Mahato RI (2003) Hydrophobization of cationic polymers for enhanced gene delivery. 6th Annual Meeting of the American Society of Gene Therapy (Washington, D.C.)

  44. Mahato RI , Wang DA, Narang AS,  Kotb M, Gaber AO, Miller DD and  Kim SW (2002) Synthesis of T-shaped water soluble lipopolymers for gene delivery. Proc. Int Symp. Control. Rel. Bioact. Mater. 29: (Seoul, Korea)

  45. Mahato RI, Henry J, Narang AS, Mitra S, Fraga D, Sabek O, Kotb M and Gaber AO (2002) Nonviral approaches for growth factor gene delivery to human pancreatic islet. Proc. Int. Symp. Controlled Rel. Bioact Mater. 29; (Seoul, Korea)

  46. Narang AS, J Henry, S Mitra, D Fraga, O Sabek, M Kotb, AO Gaber and RI Mahato (2002) Synthetic Vector for grouwth factor gene delivery to human islets. 5th ASGT Annual Meeting (Boston, MA)

  47. Wang DA, Narang AS, Kotb M, Gaber AO and Mahato RI (2002) T-Shaped water soluble lipopolymers for gene delivery. 5th ASGT Annual Meeting (Boston, MA)

  48. Furgeson DY, Yokman J, Mahato RI and Kim SW (2002) Biodistribution of insoluble lipatticulate-based system. Proc. Int. Symp. Control Rel. Bioact. Mater. 29: (Seoul, Korea)

  49. Han S-O, Lee M, Mahato RI and  Kim SW(2001) Water-Soluble Lipopolymer/p2CMVmIL-12 Complex for Cancer Treatment. AAPS Annual Meeting, Denver (October, 2001).  

  50. Furgeson DY, Mahato RI and Kim SW (2001) Synthesis and characterization of insoluble lipopolymers for gene delivery.  AAPS Annual Meeting, Denver (October, 2001)

  51. Maheshwari A, Mahato RI and  Kim SW(2001) Design of novel steroidal peptides for gene delivery.  AAPS Annual Meeting, Denver (October, 2001)

  52. Mahato RI, Lee M, Han S-O, Maheshwari A, and Kim SW (2001) Water soluble lipopolymers for interleukin-12 delivery.  28th Int Symp on Control Rel Bioactive Materials, San Diego (June 2001)

  53. *Han S-O, Mahato RI and Kim SW (2001) Water soluble lipopolymer for gene delivery.  4th Annual Meeting of the American Society of Gene Therapy, Seattle (May 30-June 4, 2001) (This abstract was selected as one of the top 3 abstract by the American Society of Gene Therapy and S-O Han was awarded $1000 at the symposium on May 30-June 3, 2001).

  54. Mahato RI, Lee M, S-O Han, Maheshwari A and  Kim SW(2001) Water soluble lipopolymer-based interleukin-12 delivery.  10th Int Symp on Recent Advances in Drug Delivery Systems, Salt Lake City (February 2001)

  55. Mahato RI, Maheshwari A, Furgeson DY,  Han S-O and Kim SW(2000) Polymeric-gene carriers for cancer treatment.  Int Symp Biomat Drug Del Syst, Cheju Island, Korea (20-22, Aug' 00)

  56. Benns JM,  Maheshwari A, Furgeson DY, Mahato RI and  Kim SW(2000) Folate-PEG-folate-graft-PEI as a gene carrier. Int Symp Biomat Drug Del Syst, Cheju Island, Korea (20-22, Aug' 00)

  57. Mahato RI, A Maheshwari A, McGregor J, Samlowski WE and Kim SW (2000) Polymeric carriers for intratumoral delivery of cytokine genes.  3rd Annual Meeting of American Society of Gene Therapy, Denver (31 May-4 June’00)

  58. *Mahato RI and Kim SW (1999) Tailor made polymeric gene carriers.  3rd Congress of Eur Assoc Clin Pharmacol Ther (EACPT), Jerusalem, Israel (3-8, Oct' 99)

  59. *Mahato RI, Anwer A, Meaney C, Tagliaferri F, Smith LC and Rolland A (1998) Factors influencing cationic lipid-based systemic gene delivery and expression.  Proc Int Symp Control Rel Bioact Mater 25: 176-177.

  60. Smith LC, Logan M, Tagliaferri F, Monera O, Mahato RI, Reimer D, Wilson E, Proctor B and Rolland A (1998) Size dependence for dispersion of DNA/cationic lipid complexes in solid tumors.  Fourth Cold Spring Harbor Gene Therapy Meeting, Sept'98.

  61. Freimark BD, Bishop JS, Blezinger HP, Deshpande DS, Mahato RI,  Florack VJ and Pericle F (1998) In vivo administration of plasmid/cationic lipid complexes induces a cytokine pattern distinct from cationic lipids and plasmids. Fourth Cold Spring Harbor Gene Therapy Meeting, Sept' 98.

  62. *Mahato RI, T Kanamaru T, Takakura Y and Hashida M (1996) Stability and disposition of phosphorothioate oligonucleotides in mice.  116th Annual Meeting of Pharmaceutical Association of Japan, Kanazawa.

  63. *Mahato RI, Takakura Y and Hashida M (1996) Disposition and gene expression of plasmid DNA complexed with cationic carriers.  Proc Intl Symp Control Rel Bioact Mater 23: 265-266.

  64. *Mahato RI, Takakura Y and Hashida M (1996) Disposition of antisense oligonucleotides to the hepatocytes using macromolecular carrier systems.  Jpn Soc Drug Del Sys, July, Kyoto.

  65. Mahato RI, Yoshida M, Nomura T, Kawabata K, Takakura Y and Hashida M (1995) Physicochemical and disposition characteristics of plasmid DNA complexed with cationic liposomes.  Proc Intl Symp Control Rel Bioact Mater 22: 418-419.

  66. Takakura Y, Mahato RI,  Kawabata K, Sawai K, Yoshida M and Hashida M (1994) Pharmacokinetics of oligonucleotides disposition in the body.  1st Intl Antisense Conf Jpn, December, Kyoto.

  67. Mahato RI , C Thies C, Lubiniewski A and Ravi VN (1994) Polymer mixture nanoparticles for ocular drug delivery.  Invest Ophthalmol Vis Sci 35: 2218.

  68. Lee VHL, LeeYH, Ohdo S,  Zhu J and Mahato RI  (1994) Dosing time influence on the ocular and systemic absorption on topically applied b-adrenergic antagonists in the pigmented rabbit. Invest. Ophthalmol. Vis. Sci. 35: 1387.

  69. Lee YH, Mahato RI, Chung RYB, and Lee VHL (1993) Corneal and noncorneal absorption of topically applied ?-adrenergic antagonists in the pigmented rabbit. Pharm. Res. 10: S359.

  70. Thies C, Mahato RI and Ravi VN (1993) Ocular drug delivery systems. Association of International Chemical Engineers Meeting.

  71. Mahato RI, Halbert GW, Willmott N and Whateley TL (1992) Preparation of microspheres for intra-articular administration.  Proc Int Symp Control Rel Bioact Mater 19: 341-342.

  72. Mahato RI, Halbert GW and Willmott N (1992) Preparation and characterization of microspherical delivery systems.  ICI Science Link Meeting, Mereside, England.

  73. Mahato RI, Willmott N and Vezin WR (1991) Preparative techniques for albumin microspheres.  Proc Int Symp Control Rel Bioact Mater 18: 375-376

  74. Mahato RI, Willmott N and  Vezin WR (1991) Preparation and characterization of albumin microspheres.  British Colloid Science Student Meeting, Nottingham.

ACADEMIC COMMITTEE ASSIGNMENTS

PhD Committees (Chair)

  1. Krishna Bhandari (2007-Present) Department of Pharmaceutical Sciences, University of Tennessee Health Science Center. Site-specific Delivery of miRNA for treating Hepatocellular Carcinoma.

  2. Michael Kofi Danquah (2007-Present) Department of Pharmaceutical Sciences, University of Tennessee Health Science Center. Polymeric Micelles for Treating Prostate Cancer.

  3. Ningning Yang (2006-Presnet) Department of Pharmaceutical Sciences, University of Tennessee Health Science Center. Site-specific Delivery of siRNA for treating Hepatitis C.

  4. Feng Li (2006-Present) Department of Pharmaceutical Sciences, University of Tennessee Health Science Center. Growth Factor and Antiapoptotic Gene Delivery to Human Pancreatic Islets for treating Type I Diabetes.

  5. Lin Zhu (2005-Present) Department of Pharmaceutical Sciences, University of Tennessee Health Science Center. Site-specific Delivery of siRNA for treatment of Hepatitis and Liver Fibrosis.

  6. Ravikiran Panakanti (2005-Present) Department of Pharmaceutical Sciences, University of Tennessee Health Science Center. Viral and Non-viral Gene Therapy and RNAi for Improving Islet Transplantation.

  7. Zhaoyang Ye (2002-2007). Department of Pharmaceutical Sciences, University of Tennessee Health Science Center. Triplex Forming Oligonucleotide Delivery to Hepatic Stellate Cells. Currently working as a Postdoctoral Fellow, Department of Biomedical Engineering, John Hopkins University, Baltimore, MD.

  8. Kun Cheng (2002-2007). Department of Pharmaceutical Sciences, University of Tennessee Health Science Center. Adenoviral Gene Delivery to Human Islets & Biodistribution and Delivery Systems of Triplex Forming Oligonucleotides for treatment of Liver Fibrosis. Currently working as an Assistant Professor, Department of Pharmaceutical Sciences, University of Missouri Kansas City, MO.

  9. Ajit S. Narang (2001-2006). Department of Pharmaceutical Sciences, University of Tennessee Health Science Center. Nonviral and Adenoviral Gene Delivery to Human and Rat Islets. Synthesis of Novel Cationic Lipids for Gene Delivery. Currently working at Bristol Myers Squibs, Inc.

PhD Committee Member:

  1. Vinayagam Kannan (2006-Present) Department of Pharmaceutical Sciences, University of Tennessee Health Science Center. Drug Delivery and Lyophilization.

  2. Hari Desu (2005-Presnt) Department of Pharmaceutical Sciences, University of Tennessee Health Science Center. Drug Delivery and Lyophilization.

  3. Murali K. Divi (2004-2007) Department of Pharmaceutical Sciences, University of Tennessee Health Science Center. Targeted Drug Delivery to Glioma Brain Tumors. Currently working at

  4. Chad Batson (2003-2005). Department of Molecular Sciences, University ot Tennessee Health Science Center.

  5. Darin Y. Furgeson (2000-2003). Department of Pharmaceutics and Pharmaceutical Chemistry, University of Utah. Structural and Functional Effects of Polyethylenimine Gene Carriers. Currently working as an Assistant Professor, Department of Pharmaceutical Sciences, University of Wisconsin, Madison, WI

  6. Jonathan M. Benns (1998 - 2001). Department of Pharmaceutics and Pharmaceutical Chemistry, University of Utah. Polymeric Gene Carriers. Currently studying law at the University of Utah, Salt Lake City.

Advisor for Summer Students and Exchange Students

  1. Daniel de Paula (Feb-August 2006) Visiting graduate student from the Faculty of Pharmaceutical Sciences of Ribeiräo Preto at the University of Säo Paulo in Brazil. Working in my laboratory as a Research Scholar to conduct research on Protein and siRNA Delivery. Currently an Assistant Professor at Universidade Estadual do Centro-Oeste - UNICENTRO, PR, Brazil.  

  2. Houssam Hajj Houssein (June-July, 2006), B.S. student from Delta State University, Cleveland, Mississippi on a project entitled, "Site-specific Delivery of TFO for Treating Liver Fibrosis (100% responsibility)

  3. Brandon Kyle Slaughter (June-July, 2005), B.S. (Biology) student from the University of Memphis on a project entitled "Genetic Modifications for Improved Islet Transplantation" (100% responsibility)

  4. Margaret M Thomson (June 25~July 18, 2003) PharmD/PhD student, Department of Pharmaceutical Science, University of Tennessee on a project entitled, “Design and synthesis of cationic lipid and liposome preparation for gene delivery (100% responsibility).

  5. Altovise Ewing (June-July2003), B.S. student from Rhodes College, Memphis on a project entitled "Adenovirus-Based hVEGF Gene Delivery to Human Islets” (100% responsibility)

  6. Deependra Mahato (January-July2002), B.S. student from Rhodes College, Memphis on a project entitled "Polymeric Carriers for Gene Delivery”(100% responsibility)

Postdoctoral Fellow

  1. Guofeng Cheng (2007-2008), Ph.D. Following his PhD training in Molecular Biology from Chinese Academy of Agricultural Sciences, he joined the University of Colorado for a postdoctoral fellowship. He worked on Genetic Modification of Human Islets from Improved Islet Transplantation and construction of adenoviral vectors. 

  2. Yong Chen (2006-Aug 07) M.S., M.D., Associate Professor at the Hepatology Institute of Huaian 4th People’s Hospital, Huaian, Jiangxu, P.R. China. He is currently working on siRNA Delivery for Treating Hepatitis B.

  3. Xiangxu Jia (2005-2006), B.S. degree in Immunology from Chongqing Third Medical Univeristy in 1992.  Following that, she obtained a M.S. degree in Immunology from Shanghai Second Medical University, in 2003. She worked on Genetic Modifications of Human Islets for Improved Transplantation. Currently she is working at Vanderbilt University, Nashville. 

  4. Neeraj Kumar (2002-2003), Ph.D. in Organic Chemistry of Indian Institutes of Technology, Roorkee, India on Synthesis and Characterization of Water Soluble Lipopolymer. Currently working as an Assistant Professor, Department of Pharmaceutical Sciences, National Institute of Pharmaceutical Education & Research, SAA Nagar, Mohali 160-062, India

  5. Dong-an Wang (2001-2002), Ph.D. in Polymer Science from Zhejiang University, China on Synthesis and Characterization of Water Soluble Lipopolymer. Currently working as an Assistant Professor, Division of Bioengineering, Nanyang Technological University, Singapore.

  6. Suchareeta Mitra (2001-2002), Ph.D. in Biochemistry/Zoology from Delhi University on Gene Delivery to Human Islets. Currently working as a postdoctoral fellow at the Department of Molecular Sciences, University of Tennessee Health Science Center, Memphis

SCHOOL/COLLEGE COMMITTEE ASSIGNMENTS

·        Member, Graduate Curriculum Committee (2003-present), University of Tennessee Health Science Center,  Memphis, TN

·        Member, College of Pharmacy Curriculum Committee (2005-Present), University of Tennessee Health Science Center,  Memphis, TN

·        Member, Faculty Development Committees (2002-Present), University of Tennessee Health Science Center,  Memphis, TN